YK-4-279

Unlocking the future of hepatocellular carcinoma treatment: A comprehensive analysis of disulfidptosis-related lncRNAs for prognosis and drug screening

**Background:** Disulfidptosis, a form of cell death triggered by disulfide stress, is characterized by the breakdown of cytoskeletal proteins and F-actin due to the excessive accumulation of disulfides in cells. The role of long non-coding RNAs (lncRNAs) associated with disulfidptosis in the progression of hepatocellular carcinoma (HCC) remains unclear. This study aims to investigate the significance of lncRNAs in HCC development.

**Methods:** We obtained HCC-related lncRNAs and clinical data from The Cancer Genome Atlas (TCGA). Disulfidptosis-related genes were identified using co-expression analysis, Cox regression, and Lasso regression. A prognostic model was then developed for further validation.

**Results:** The disulfidptosis-related lncRNA risk model effectively distinguished between high- and low-risk HCC patients, as confirmed by survival analysis, independent prognostic evaluation, concordance index (C-index), receiver operating characteristic (ROC) curves, and Kaplan-Meier plots. Additionally, we observed differences in the response to immune therapies and anticancer drugs between the two patient groups. Notably, drugs such as GDC0810, Osimertinib, Paclitaxel, and YK-4-279 were more effective in the high-risk group.

**Conclusion:** In summary, we developed a risk model based on disulfidptosis-related lncRNAs that offers valuable insights for improving the diagnosis and treatment of HCC.